This is a companion post to a recently written one entitled, “Blogging About NO Clogging.” That post describes how the EpicentRx lead small molecule, RRx-001 (nibrozetone), releases the gaseous vasodilator, nitric oxide (NO), only under hypoxic/ischemic conditions to increase oxygen and nutrient delivery locally, which wholly differentiates it from approved nitrate esters like nitroglycerin, for example, that release NO systemically throughout the whole body.
This post lists out several of the conditions that are related to occluded or clogged blood flow from NO-deficiency or depletion and, hence, that may benefit from treatment with RRx-001 (nibrozetone). They include in no order, sickle cell disease, peripheral artery disease (PAD), diabetes, atherosclerosis, heart failure, pulmonary hypertension, erectile dysfunction, chronic kidney disease, retinopathies, stroke, myocardial infarction, chronic obstructive pulmonary disease (COPD), mitochondrial disorders, hypertension and neurodegenerative diseases.
If at this point you were to exclaim, “NO way!” at the sheer number of these diseases, we would nod vigorously in agreement also because the way to better health and longevity is possibly through targeted nitric oxide delivery with an agent like RRx-001 (nibrozetone).
NO way, indeed.